RB1 and non-small cell lung carcinoma: In addition, almost 29.7% of the patients had no clinically applicable mutations of NSCLC, among which CEBPA, RB1, TCF7L2 were the most common mutated genes (Figure 4E), thus providing potential targets for the research and development of new targeted drugs.